NASDAQ:SGMOSangamo Therapeutics Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Sangamo Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $12.33 +0.61 (+5.20 %) (As of 08/7/2020 04:00 PM ET) Add Compare Share Today's Range$11.54Now: $12.33▼$12.5950-Day Range$8.73MA: $10.24▼$11.7252-Week Range$4.81Now: $12.33▼$12.91Volume2.15 million shsAverage Volume1.70 million shsMarket Capitalization$1.74 billionP/E RatioN/ADividend YieldN/ABeta2.28 ProfileAnalyst RatingsAdvanced ChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Sangamo Therapeutics, Inc. focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation. Its therapeutic products which are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; SB-FIX for the treatment of hemophilia B; ST-400 for the treatment of beta-thalassemia; and SB-318 for the treatment of Mucopolysaccharidosis Type I and SB-913 for the treatment of Mucopolysaccharidosis Type II, which are lysosomal storage disorders (LSDs). The company also develops ST-920, a gene therapy for fabry disease. It has collaboration and license agreements with Kite Pharma, Inc., Pfizer Inc., Bioverativ Inc., and Shire International GmbH, as well as license partnerships with Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc., F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.Read More Beat the Market (BTM) Rank™ 1.4 Analyst's Opinion Consensus RatingSangamo Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.75, and is based on 3 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $12.50, Sangamo Therapeutics has a potential upside of 1.4% from its current price of $12.33.Amount of Analyst CoverageSangamo Therapeutics has only been the subject of 3 research reports in the past 90 days. Previous Next 2.5 Community Rank Outperform VotesSangamo Therapeutics has received 410 “outperform” votes. (Add your “outperform” vote.)Underperform VotesSangamo Therapeutics has received 402 “underperform” votes. (Add your “underperform” vote.)Community SentimentSangamo Therapeutics has received 50.49% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Sangamo Therapeutics and other stocks. Vote “Outperform” if you believe SGMO will outperform the S&P 500 over the long term. Vote “Underperform” if you believe SGMO will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldSangamo Therapeutics does not currently pay a dividend.Dividend GrowthSangamo Therapeutics does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Sangamo Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.80% of the stock of Sangamo Therapeutics is held by insiders.Percentage Held by Institutions52.90% of the stock of Sangamo Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Sangamo Therapeutics are expected to decrease in the coming year, from ($0.52) to ($1.07) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Sangamo Therapeutics is -14.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Sangamo Therapeutics is -14.86, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSangamo Therapeutics has a P/B Ratio of 3.40. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 1.4Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.98 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Biological products, except diagnostic Sub-IndustryBiotechnology SectorMedical Current SymbolNASDAQ:SGMO Previous Symbol CUSIP80067710 CIK1001233 Webwww.sangamo.com Phone510-970-6000Debt Debt-to-Equity Ratio0.08 Current Ratio7.23 Quick Ratio5.98Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$102.43 million Price / Sales16.97 Cash FlowN/A Price / Cash FlowN/A Book Value$3.63 per share Price / Book3.40Profitability EPS (Most Recent Fiscal Year)($0.85) Net Income$-95,190,000.00 Net Margins-91.17% Return on Equity-23.12% Return on Assets-14.74%Miscellaneous Employees302 Outstanding Shares140,990,000Market Cap$1.74 billion Next Earnings Date11/4/2020 (Estimated) OptionableOptionable $12.33 +0.61 (+5.20 %) (As of 08/7/2020 04:00 PM ET) 30 days | 90 days | 365 days | Advanced Chart Receive SGMO News and Ratings via Email Sign-up to receive the latest news and ratings for SGMO and its competitors with MarketBeat's FREE daily newsletter. Sangamo Therapeutics (NASDAQ:SGMO) Frequently Asked Questions How has Sangamo Therapeutics' stock been impacted by COVID-19 (Coronavirus)? Sangamo Therapeutics' stock was trading at $7.02 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SGMO stock has increased by 75.6% and is now trading at $12.33. View which stocks have been most impacted by Coronavirus. Do Wall Street analysts recommend investors buy shares of Sangamo Therapeutics? 4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sangamo Therapeutics in the last year. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Sangamo Therapeutics. When is Sangamo Therapeutics' next earnings date? Sangamo Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, November 4th 2020. View our earnings forecast for Sangamo Therapeutics. How were Sangamo Therapeutics' earnings last quarter? Sangamo Therapeutics Inc (NASDAQ:SGMO) posted its quarterly earnings results on Wednesday, August, 5th. The biopharmaceutical company reported ($0.26) EPS for the quarter, missing the Zacks' consensus estimate of $0.41 by $0.67. The biopharmaceutical company had revenue of $21.55 million for the quarter, compared to analysts' expectations of $74.50 million. Sangamo Therapeutics had a negative return on equity of 23.12% and a negative net margin of 91.17%. View Sangamo Therapeutics' earnings history. What price target have analysts set for SGMO? 4 Wall Street analysts have issued 12 month price objectives for Sangamo Therapeutics' stock. Their forecasts range from $11.00 to $14.00. On average, they anticipate Sangamo Therapeutics' share price to reach $12.50 in the next twelve months. This suggests a possible upside of 1.4% from the stock's current price. View analysts' price targets for Sangamo Therapeutics. Has Sangamo Therapeutics been receiving favorable news coverage? News coverage about SGMO stock has trended extremely negative recently, InfoTrie Sentiment reports. InfoTrie rates the sentiment of media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Sangamo Therapeutics earned a media sentiment score of -4.8 on InfoTrie's scale. They also assigned news coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the stock's share price in the near term. View the latest news about Sangamo Therapeutics. Who are some of Sangamo Therapeutics' key competitors? Some companies that are related to Sangamo Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX). View all competitors. What other stocks do shareholders of Sangamo Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Sangamo Therapeutics investors own include NVIDIA (NVDA), Crispr Therapeutics (CRSP), Advanced Micro Devices (AMD), Micron Technology (MU), Novavax (NVAX), Gilead Sciences (GILD), Brainstorm Cell Therapeutics (BCLI), Alibaba Group (BABA), Editas Medicine (EDIT) and Intel (INTC). Who are Sangamo Therapeutics' key executives? Sangamo Therapeutics' management team includes the following people: Dr. Alexander D. Macrae, CEO, Pres & Director (Age 56)Ms. Kathy Y. Yi, EVP, CFO, Principal Accounting Officer & Sec. (Age 47)Dr. Edward R. Conner, Sr. VP & Chief Medical Officer (Age 46)Dr. Edward Rebar, Sr. VP & CTOMr. McDavid Stilwell, VP of Corp. Communications & Investor Relations What is Sangamo Therapeutics' stock symbol? Sangamo Therapeutics trades on the NASDAQ under the ticker symbol "SGMO." Who are Sangamo Therapeutics' major shareholders? Sangamo Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Great Lakes Advisors LLC (0.60%), Rhenman & Partners Asset Management AB (0.48%), Candriam Luxembourg S.C.A. (0.26%), Swiss National Bank (0.18%), Platinum Investment Management Ltd. (0.17%) and Frontier Capital Management Co. LLC (0.16%). Company insiders that own Sangamo Therapeutics stock include Edward R Conner, H Stewart Parker, Joseph S Zakrzewski, Kathy Yi and Stephen George Dilly. View institutional ownership trends for Sangamo Therapeutics. Which institutional investors are selling Sangamo Therapeutics stock? SGMO stock was sold by a variety of institutional investors in the last quarter, including SG Americas Securities LLC, Candriam Luxembourg S.C.A., Creative Planning, DAVENPORT & Co LLC, Rhenman & Partners Asset Management AB, Frontier Capital Management Co. LLC, Dupont Capital Management Corp, and Edge Wealth Management LLC. View insider buying and selling activity for Sangamo Therapeutics. Which institutional investors are buying Sangamo Therapeutics stock? SGMO stock was bought by a variety of institutional investors in the last quarter, including Great Lakes Advisors LLC, UBS Group AG, WINTON GROUP Ltd, Rafferty Asset Management LLC, Trexquant Investment LP, Russell Investments Group Ltd., Virtu Financial LLC, and Swiss National Bank. Company insiders that have bought Sangamo Therapeutics stock in the last two years include H Stewart Parker, and Joseph S Zakrzewski. View insider buying and selling activity for Sangamo Therapeutics. How do I buy shares of Sangamo Therapeutics? Shares of SGMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Sangamo Therapeutics' stock price today? One share of SGMO stock can currently be purchased for approximately $12.33. How big of a company is Sangamo Therapeutics? Sangamo Therapeutics has a market capitalization of $1.74 billion and generates $102.43 million in revenue each year. The biopharmaceutical company earns $-95,190,000.00 in net income (profit) each year or ($0.85) on an earnings per share basis. Sangamo Therapeutics employs 302 workers across the globe. What is Sangamo Therapeutics' official website? The official website for Sangamo Therapeutics is www.sangamo.com. How can I contact Sangamo Therapeutics? Sangamo Therapeutics' mailing address is 7000 MARINA BLVD, BRISBANE CA, 94005. The biopharmaceutical company can be reached via phone at 510-970-6000 or via email at [email protected] This page was last updated on 8/9/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
